Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.
Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.
复制标题
DOI：
10.4103/0976-500x.119704
复制
发表时间：
2013-10
影响因子：
0.2
通讯作者：
Abidi A
中科院分区：
文献类型：
--
作者：
Abidi A
近年来，前列腺癌的治疗取得了长足的发展，在过去的几年里，许多新的治疗药物已经被批准。对于转移性去势耐药前列腺癌(MCRPC)患者，最初多西紫杉醇是标准化疗方案，但一旦对多西紫杉醇耐药，没有任何治疗方法能提高生存率。这种情况在2010年6月发生了变化，当时美国食品和药物管理局(FDA)批准Cabazitaxel作为对多西紫杉醇耐药的mCRPC患者的新治疗方案。卡氮紫杉醇是一种新型的微管蛋白结合紫杉烷，与P-糖蛋白亲和力较差，可降低耐药几率。它已在多西他赛耐药肿瘤的临床前、I期、II期和III期临床研究中显示出抗肿瘤活性。本文综述了卡巴紫杉醇治疗去势耐药前列腺癌的背景、药效学、动力学和临床进展。该药物在其他肿瘤中的未来开发和合理使用正在进行治疗研究。
Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy but once they became refractory to docetaxel, no treatment improved survival. This scenario changed in June 2010 when the US Food and Drug Administration (FDA) approved Cabazitaxel as a new therapeutic option for patients with mCRPC resistant to docetaxel. Cabazitaxel, being a novel tubulin-binding taxane with poor affinity for P-glycoprotein, decreases the chances of resistance. It has shown antitumor activity in preclinical, phase I, II and III clinical studies in docetaxel-resistant tumors. This article summarises the background, pharmacodynamic, kinetics and clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Future development and rational use of this drug in other tumors is under therapeutic investigation.